单克隆免疫球蛋白沉积病治疗后的肾脏结局评估:强调需要共识方法
该回顾性分析纳入34例单克隆免疫球蛋白沉积病(MIDD)患者,多数接受硼替佐米和自体干细胞移植,28例可评估者中26例(94%)达非常好的部分血液学缓解或更好。需同时使用IMWG(基于eGFR)和淀粉样变(基于蛋白尿)标准才能全面评估肾脏缓解,联合标准下28例中22例(79%)达肾脏缓解。孤立性蛋白尿者6例全部(100%)达肾脏缓解,孤立性eGFR下降者13例中7例(54%)达肾脏缓解;基线eGFR可预测肾脏缓解(p=.02)和生存(p=.02)。
要点
- MIDD患者血液学缓解用IMWG共识标准评估,肾脏缓解缺乏统一标准。
- 联合IMWG(eGFR)和淀粉样变(蛋白尿)标准可更全面评估肾脏缓解。
- 孤立性蛋白尿可能是MIDD早期表现,与可逆性肾损伤相关。
核心结论
- 同时使用IMWG(基于eGFR)和淀粉样变(基于蛋白尿)标准才能捕获MIDD患者的肾脏缓解。
- 基线eGFR可预测肾脏缓解(p=.02)和生存(p=.02),而血液学缓解(完全缓解 vs. 非完全缓解)未显示预测作用,可能因血液学缓解率高。
- 需要使用统一肾脏缓解标准的前瞻性研究来优化MIDD管理。
研究设计与样本
- 回顾性分析34例单克隆免疫球蛋白沉积病(MIDD)患者的肾脏结局。
- 多数患者接受硼替佐米和自体干细胞移植治疗。
- 中位随访110个月。
主要发现
- 28例可评估患者中26例(94%)达非常好的部分血液学缓解或更好。
- 28例可评估患者中6例(21%)为孤立性蛋白尿,13例(46%)为孤立性eGFR下降。
- 联合两种标准,28例中22例(79%)达肾脏缓解,包括7例透析患者中2例停止透析。
- 孤立性蛋白尿6例全部(100%)达肾脏缓解,孤立性eGFR下降13例中7例(54%)达肾脏缓解。
- 中位总生存136个月(95% CI:79-NR),中位肾脏生存未达到。
关键数值与推荐
- 血液学缓解采用国际骨髓瘤工作组(IMWG)共识标准评估。
- 肾脏缓解分别采用IMWG(基于eGFR)和淀粉样变(基于蛋白尿)标准评估。
- 基线eGFR按四分位数预测肾脏缓解(p=.02)和生存(p=.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 需要前瞻性研究使用统一肾脏缓解标准来优化MIDD管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal immunoglobulin deposition disease (MIDD), often associated with plasma cell dyscrasias, predominantly affects the kidneys. In this disease, hematologic response (HR) to treatment can be reliably assessed by International Myeloma Working Group (IMWG) consensus criteria, while uniform criteria for assessing renal response are lacking. We report a retrospective analysis of renal outcomes among 34 patients with MIDD. With most patients treated with bortezomib and autologous stem cell transplantation, 26 of 28 (94%) achieved very good partial HR or better. We demonstrate that both IMWG (based on estimated glomerular filtration rate, eGFR) and amyloid (based on proteinuria) criteria are needed to capture renal response: among 28 evaluable patients, 6 (21%) had isolated proteinuria, while 13 (46%) had isolated decreased eGFR. Using both criteria, which were concordant in patients with both decreased eGFR and proteinuria, 22 of 28 patients (79%) achieved a renal response, including 2 of 7 discontinuing dialyses. All 6 patients (100%) with isolated proteinuria and 7 of 13 (54%) with isolated decreased eGFR achieved renal response, suggesting that isolated proteinuria is an early manifestation of MIDD associated with reversible renal damage. Baseline eGFR predicted renal response (p = .02 by quartile) and survival (p = .02), while HR (CR vs. non-CR) did not, probably because of high HR rate. With a median follow-up of 110 months, the median overall survival was 136 months (95% CI: 79-NR) and median renal survival had not been reached. Prospective studies using uniform renal response criteria are needed to optimize the management of MIDD.
引用
- Pianko MJ, Tiutan T, Derkach A, et al. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. Am J Hematol. 2023. PMID: 36588413. doi:10.1002/ajh.26801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。